Fact CheckerSign in

NCT06080399Completed

Personality and Quality of Life Amelioration After Continuous Subcutaneous Apomorphine Infusion in Parkinson's Disease

Could Psycho-bio-social Context and Personality be a Predictive Factor of Quality of Life Amelioration After Continuous Subcutaneous Apomorphine Infusion in Parkinson's Disease Patients? - PERSO-PERF Study

Source: ClinicalTrials.gov · Last updated 12 May 2026

Brief summary (registry, in English)

Since our previous study has shown that some personality dimensions were associated with Quality of Life (QoL) amelioration after Deep Brain Stimulation (DBS) in Parkinson's disease (PD), the investigators aim to evaluate the impact of personality dimensions on therapeutic response after another second-line treatment: the continuous subcutaneous apomorphine infusion (CSAI). Moreover, the investigators would like to evaluate the potential evolution of personality dimensions through CSAI. The investigators also aim to evaluate other bio-psycho-social factors (representations of the disease, ways of copying and social support) influence on QoL amelioration after DBS.

Status (registry)
Completed
Study type
Observational
Enrollment
70 (actual)
First submitted
6 Oct 2023
Start date
15 Feb 2024
Primary completion date
30 Mar 2026
Lead sponsor
University Hospital, Toulouse
NCT number
NCT06080399

What you commit to

  • Study type: Observational
  • Participants enrolled: 70
  • From 15 Feb 2024 to the primary completion date, 30 Mar 2026
  • 10 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • Patients presenting an atypical parkinsonian syndrome Patients having a Deep Brain Stimulation
  • Patients with a psychiatric disease such as bipolar disorder or delusions linked to a dopaminergic psychosis
  • Patient with a serious pathology (e.g. cancer) or a health condition which could interfere with the assessment of their quality of life, at the discretion of the investigator upon inclusion

Other

  • Patients presenting a cognitive deficit attested by a score to the Montreal Cognitive Assessment inferior to 24, solely during the inclusion (baseline - V0)
  • Patients under guardianship, curatorship or safeguard of justice
  • Patients under exclusion period from another study

Who the study is looking for

  • Parkinson's disease patients as defined by the United Kingdom Parkinson's disease Brain Bank (UKPDSBB) criteria and aged from 40 to 75 years old (included)
  • Patients with motor fluctuations and/or invalidating dyskinesia and awaiting CSAI establishment in the context of their usual care for PD
  • Patients affiliated to a social security system

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (10)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Chu de Lyon
Coordinator of this site? Confirm its status
BronFranceUnknown status
Hopital Gabriel Montpied
Coordinator of this site? Confirm its status
Clermont-FerrandFranceUnknown status
CHU de Grenoble
Coordinator of this site? Confirm its status
GrenobleFranceUnknown status
CHU Limoges
Coordinator of this site? Confirm its status
LimogesFranceUnknown status
CHU de Nancy
Coordinator of this site? Confirm its status
NancyFranceUnknown status
CHU de Nice
Coordinator of this site? Confirm its status
NiceFranceUnknown status
CHU de Poitiers
Coordinator of this site? Confirm its status
PoitiersFranceUnknown status
CHU de Rennes
Coordinator of this site? Confirm its status
RennesFranceUnknown status
CHU de Rouen
Coordinator of this site? Confirm its status
RouenFranceUnknown status
CHU de Toulouse
Coordinator of this site? Confirm its status
ToulouseFranceUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.